Roger Dansey, Seagen interim CEO
July 29, 2022 07:08 AM EDT
Pharma

Seagen stays qui­et on M&A as it push­es Keytru­da-Pad­cev com­bo, con­tin­ues CEO search

Tyler Patchen

News Reporter

Seagen’s keep­ing qui­et on the M&A front as ru­mors fly around a po­ten­tial Mer­ck buy­out. In­stead, the Wash­ing­ton State-based phar­ma com­pa­ny used its Q2 call …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

Three drug­mak­ers sue US over 340B dis­counts to STD clin­ics they al­lege don’t qual­i­fy

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

Ver­tex gets 'van­za triple' ap­proval and Trikaf­ta ex­pan­sion — with boxed warn­ings

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

Bris­tol My­er­s' TYK2 in­hibitor suc­ceeds in pair of Phase 3 pso­ri­at­ic arthri­tis tri­als

A service from the Financial Times